Bone marrow edema does not increase due to intense physical activity, study finds
Can't see this email? View it online
   
  January 11, 2018  
  Rheumatology  
  The latest rheumatology news from News Medical  
 Bone marrow edema does not increase due to intense physical activity, study findsBone marrow edema does not increase due to intense physical activity, study finds
 
A recent study published in Rheumatology finds that osteitis/bone marrow edema as measured by magnetic resonance imaging was present in healthy people. However, it did not significantly increase due to intense physical activity.
 
 
 Treatment for skin cancer could be more effective if combined with arthritis drugTreatment for skin cancer could be more effective if combined with arthritis drug
 
Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.
 
   New HSS study may signal hope for patients suffering from sclerodermaNew HSS study may signal hope for patients suffering from scleroderma
 
Scleroderma is a terribly debilitating disease with no effective treatments and the mortality rates are still upwards of 20%-50%, the highest of any rheumatic disease.
 
   Rare gene mutation gives rise to low sensitivity to painRare gene mutation gives rise to low sensitivity to pain
 
Researchers at University College London have identified a rare gene mutation in an Italian family who have little sensitivity to some forms of pain. Chronic pain caused by conditions such as lower back pain and osteoarthritis is one of the most prominent causes of disability worldwide, as assessed by the Global Burden of Disease reviews.
 
   New classification criteria offers faster, more accurate path to diagnosing myositis diseasesNew classification criteria offers faster, more accurate path to diagnosing myositis diseases
 
The ability to diagnose myositis diseases and treat them properly just improved immensely. For more than 40 years, the criteria physicians have used to diagnose most myositis diseases has been based on expert opinion, not hard science.
 
 Biosimilars, biologics and new legal challenges for RA treatments
 
Early last winter, Pfizer launched its new rheumatoid arthritis treatment, Inflectra, pricing it 15 percent below the $4,000-a-dose wholesale price of Remicade, the drug for which it is a close copy.
 
 
 UGR study paves way for development of better analgesics to treat joint pain
 
UGR study paves way for development of better analgesics to treat joint painResearchers from the University of Granada have led a novel study in mice which shows that neurons mediating joint pain are different from those mediating cutaneous pain.